Month: September 2026

Maranello (Italy), September 14, 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on September 1, 2026, as the third tranche of the multi-year share buyback program of approximately Euro 3.5 billion expected to be executed by 2030 in line with the disclosure made during the 2025 Capital Markets Day (the “Third Tranche”), the additional common shares – reported in aggregate form, on a daily basis – on the Euronext Milan (EXM) and on the New York Stock Exchange (NYSE) as follows:

	EXM			NYSE				Total
Trading	Number of common shares purchased	Average price per share	Consideration excluding fees	Number of common shares purchased	Average price per share	Consideration excluding fees	Consideration excluding fees	Number of common shares purchased	Average price per share	Consideration excluding fees
Date		excluding fees			excluding fees				excluding fees
(d/m/y)		(€)	(€)		($)	($)	(€)*		(€)*	(€)*
07/09/2026	7,000	356.1103	2,492,772.10	–	–	–	–	7,000	356.1103	2,492,772.10
08/09/2026	7,600	352.6602	2,680,217.52	–	–	–	–	7,600	352.6602	2,680,217.52
09/09/2026	7,100	348.7243	2,475,942.53	6,207	402.7436	2,499,829.53	2,145,408.11	13,307	347.2872	4,621,350.64
10/09/2026	7,400	351.9514	2,604,440.36	–	–	–	–	7,400	351.9514	2,604,440.36
11/09/2026	7,400	353.7805	2,617,975.70	–	–	–	–	7,400	353.7805	2,617,975.70
	36,500	352.6397	12,871,348.21	6,207	402.7436	2,499,829.53	2,145,408.11	42,707	351.6228	15,016,756.32
Total

(*) translated at the European Central Bank EUR/USD exchange reference rate as of the date of each purchase
        
Since the announcement of such Third Tranche till September 11, 2026, the total invested consideration has been:

• Euro 20,807,256.73 for No. 58,800 common shares purchased on the EXM
• USD 7,999,733.07 (Euro 6,887,538.65*) for No. 19,548 common shares purchased on the NYSE.

As of September 11, 2026 the Company held in treasury No. 1,669,152 common shares, net of shares assigned under the Company’s equity incentive plan, corresponding to 0.94% of the then total issued common shares. Including the special voting shares, the Company held in treasury 0.71% of the then total issued share capital.

Since January 5, 2026, start date of the multi-year share buyback program of approximately Euro 3.5 billion announced during the 2025 Capital Markets Day, until September 11, 2026, the Company has purchased a total of 1,779,532 own common shares on EXM and NYSE, including transactions for Sell to Cover, for a total consideration of Euro 538,452,100.59.

A comprehensive overview of the transactions carried out under the buyback program, as well as the details of the above transactions, are available on Ferrari’s corporate website under the Buyback Programs section (https://www.ferrari.com/en-EN/corporate/buyback-programs).

For further information:
Ferrari Media & PR
Email: media@ferrari.com

Attachment

• FNV BB PR 14 Sep 2026 ENG

(In accordance with article 5 of Regulation (EU) No 596/2014 on Market Abuse Regulation and article 3(3) of Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 through regulatory technical standards concerning the conditions applicable to buyback programmes and stabilisation measures)

As announced on Thursday 30 July 2026, Ayvens started on Friday 31 July 2026, an ordinary share buyback programme for a maximum amount of EUR 450 million for the purpose of shares cancellation.

Ayvens received all necessary authorisations from supervisory authorities. The share buyback programme will be carried out in accordance with the provisions set out in the EU Regulation n°596/2014 of the European Parliament and of the Council of April 16th 2014, on market abuse, as modified, and its implementing provisions, and within the limits of the authorization granted to Ayvens to purchase shares and cancel such shares pursuant to the 19th and 20th resolutions of the combined General Shareholders’ Meeting held on 13 May 2026. The share buyback is performed on the trading platforms on which Ayvens shares are listed for trading or are traded, including the regulated market of Euronext Paris. The liquidity contract concluded with BNP Paribas Exane has been suspended throughout the buyback period.

Purchases performed from 7 September to 11 September 2026 are described below. As of 11 September 2026, Ayvens has completed 18.13% of its share buyback programme, representing 0.92%¹ of its share capital.

Issuer name: Ayvens SA – LEI 969500E7V019H9NP7427

Reference of the financial instrument: ISIN FR0013258662

Period: from 7 September to 11 September 2026

Purchases performed by Ayvens SA during the period

Issuer’s name	Issuer’s identifying code	Transaction date	Identifying code of financial instrument	Total daily volume (in number of shares)	Daily weighted average purchase price of shares	Market (MIC code)
AYVENS SA	969500E7V019H9NP7427	7-Sep-26	FR0013258662	179,700	11.1762	XPAR
AYVENS SA	969500E7V019H9NP7427	7-Sep-26	FR0013258662	93,900	11.1648	CEUX
AYVENS SA	969500E7V019H9NP7427	7-Sep-26	FR0013258662	21,100	11.1685	TQEX
AYVENS SA	969500E7V019H9NP7427	7-Sep-26	FR0013258662	34,300	11.1700	AQEU
AYVENS SA	969500E7V019H9NP7427	8-Sep-26	FR0013258662	186,900	10.6467	XPAR
AYVENS SA	969500E7V019H9NP7427	8-Sep-26	FR0013258662	97,550	10.6441	CEUX
AYVENS SA	969500E7V019H9NP7427	8-Sep-26	FR0013258662	21,350	10.6550	TQEX
AYVENS SA	969500E7V019H9NP7427	8-Sep-26	FR0013258662	34,800	10.6516	AQEU
AYVENS SA	969500E7V019H9NP7427	9-Sep-26	FR0013258662	188,900	10.5367	XPAR
AYVENS SA	969500E7V019H9NP7427	9-Sep-26	FR0013258662	99,700	10.5400	CEUX
AYVENS SA	969500E7V019H9NP7427	9-Sep-26	FR0013258662	21,375	10.5759	TQEX
AYVENS SA	969500E7V019H9NP7427	9-Sep-26	FR0013258662	35,000	10.5684	AQEU
AYVENS SA	969500E7V019H9NP7427	10-Sep-26	FR0013258662	196,700	10.7627	XPAR
AYVENS SA	969500E7V019H9NP7427	10-Sep-26	FR0013258662	102,850	10.7483	CEUX
AYVENS SA	969500E7V019H9NP7427	10-Sep-26	FR0013258662	21,850	10.7403	TQEX
AYVENS SA	969500E7V019H9NP7427	10-Sep-26	FR0013258662	35,950	10.7373	AQEU
AYVENS SA	969500E7V019H9NP7427	11-Sep-26	FR0013258662	205,200	10.8049	XPAR
AYVENS SA	969500E7V019H9NP7427	11-Sep-26	FR0013258662	94,463	10.7925	CEUX
AYVENS SA	969500E7V019H9NP7427	11-Sep-26	FR0013258662	22,900	10.7965	TQEX
AYVENS SA	969500E7V019H9NP7427	11-Sep-26	FR0013258662	35,627	10.7982	AQEU
			TOTAL	1,730,115	10.7801

Aggregated presentation by day and market

About Ayvens
Ayvens is a leading global sustainable mobility player committed to making life flow better. We’ve been improving mobility for decades, providing full-service leasing, flexible subscription services, fleet management and multi-mobility solutions to large international corporates, SMEs, professionals and private individuals.		With more than 13,000 employees across 40 countries, Ayvens manages 3.1 million vehicles and the world’s largest multi-brand EV fleet. The company is listed on Compartment A of Euronext Paris (ISIN: FR0013258662; Ticker: AYV). Societe Generale Group is Ayvens’ majority shareholder. Find out more at ayvens.com

Press contact
Elise Boorée Communications Department Tel: +33 (0)6 25 01 24 16 elise.booree@ayvens.com

---

¹ Ratio between the number of shares repurchased and the 783,862,091 shares comprising the current share capital.

Attachment

• Report-on-share-buyback- 7 September to 11 September 2026

• GENFIT’s acquisition of nangibotide, a differentiated late-stage asset, reinforces the Company’s portfolio of innovative therapies addressing high unmet medical needs
• The investigation in Phase 2 is supported by a robust scientific and clinical foundation around the TREM-1 pathway and the asset’s profile:
  • Strong knowledge of nangibotide’s biological pathway
  • Multiple efficacy signals already observed with nangibotide across three Phase 2 clinical trials in septic shock and COVID-19 subjects, including a statistically significant reduction in mortality in severe COVID-19 and significant improvements in SOFA score from baseline in septic shock
  • Overall favorable safety and tolerability profile demonstrated across four clinical trials, with more than 400 subjects exposed to nangibotide, and no meaningful differences versus placebo in safety outcomes
• Nangibotide expected to enter a Phase 2a proof-of-concept study in ACLF in the fourth quarter of 2026, with data readout targeted in 2027
• More details to be disclosed during The Liver Meeting® in Denver, in November 2026

Lille (France), Cambridge (Massachusetts, United States), September 14, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the strengthening of its pipeline through the acquisition of nangibotide in summer 2026, and its plan to investigate nangibotide in a Phase 2 clinical trial for the treatment of Acute-on-Chronic Liver Failure (ACLF).

A clinical and regulatory foundation supporting rapid development
Nangibotide has an extensive human safety package, built on experience from more than 400 subjects across acute inflammatory conditions, supporting the program to move directly into proof-of-concept evaluation in ACLF.

In the post-hoc analysis of Phase 2 clinical trials conducted in septic shock and COVID-19, nangibotide demonstrated multiple efficacy signals, including a statistically significant reduction in mortality.

The existing regulatory and CMC (Chemistry, Manufacturing, and Controls) packages for nangibotide are also well advanced to support rapid clinical development in ACLF, allowing the program to build on an extensive clinical safety database and a mature, well-established manufacturing platform.

Pascal Prigent, CEO of GENFIT, commented: “We believe ACLF represents one of the most significant unmet needs in liver disease. Nangibotide could be a strategic fit for our ACLF portfolio and further reinforces our leadership position in this field. We look forward to advancing the program toward proof of concept.”

Next steps

GENFIT expects to initiate a Phase 2 proof of concept trial in the fourth quarter of 2026, with data available in 2027. The Company will provide more details during The Liver Meeting ® in Denver, in November 2026.

END

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-Chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.¹   Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the development and potential therapeutic profile of nangibotide, the potential role of TREM-1 in Acute-on-Chronic Liver Failure (ACLF), the initiation, design, conduct, timing and results of future clinical trials, including the planned Phase 2a proof-of-concept study in ACLF, the potential clinical benefits, safety profile and therapeutic value of nangibotide, the potential relevance on future clinical investigations of efficacy signals and safety data observed in prior clinical studies conducted in other indications, the expected timing of data readouts, regulatory interactions and future development activities, as well as the Company’s strategic plans and objectives. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties relating to the successful integration and development of nangibotide following its acquisition by the Company; the ability to initiate and complete clinical trials within anticipated timelines; uncertainties associated with patient enrollment, site activation and trial execution; the possibility that clinical trial results may not support further development of nangibotide; safety findings that may emerge during future studies and; regulatory requirements, interactions and decisions and manufacturing and supply considerations. No assurance can be given that the planned Phase 2a study will demonstrate efficacy, safety, or clinical benefit, nor that nangibotide will ultimately receive regulatory approval for any indication. Those risks and uncertainties also include those discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors

Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 |
jean-christophe.marcoux@genfit.com

Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com

GENFIT | Media

Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com         

---

1 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®

Attachment

• GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF